ARS Pharmaceuticals Faces Class Action Over Failed Insurance Coverage

The complaint filed by Robbins LLP alleges that ARS Pharmaceuticals repeatedly assured investors that CVS Caremark would extend insurance coverage for its needle-free epinephrine product by July 1, 2026. These assurances were intended to capture the peak summer and back-to-school allergy seasons. However, the company revealed on June 24 that those coverage goals would not be met, with CVS Caremark postponing any decision until January 2027.

Following the disclosure, ARS stock plummeted from $10.54 to $8.02 per share in a single day, marking a loss of approximately 23.9%. Shareholders who suffered financial losses during the designated period have until October 5, 2026, to apply for lead plaintiff status. The law firm notes that representation is conducted on a contingency basis, meaning investors do not incur out-of-pocket legal expenses.